Articles from GenVivo, Inc.

SAN MARINO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient’s immune system against the entire repertoire of their own tumor antigens, announces the presentation of GEN2 Phase 1 clinical trial results in adult patients with advanced solid tumors (NCT06391918), at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 7-9, in National Harbor, MD. 

SAN MARINO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient’s immune system against the entire repertoire of their own tumor antigens, today announces the appointment of Dr. Noriyuki “Nori” Kasahara as Chief Scientific Officer (CSO).

SAN MARINO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient’s immune system against the breadth of the patient’s own tumor antigens, is presenting data on two non-integrating versions of their retroviral vector technology at the 2025 Retroviruses Meeting, May 19th – 24th, at Cold Springs Harbor Laboratory (CSHL) in New York.

SAN MARINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) --  GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient’s immune system against the breadth of the patient’s own tumor antigens, is presenting updated Phase 1 clinical data on GEN2 and preclinical data on GEN-1013 at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, May 13th – 17th, in New Orleans, LA.

PASADENA, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that fights cancer by activating the patient’s immune system against the breadth of the patient’s own tumor antigens, is presenting compelling preclinical data on GEN-1013, an Interleukin-12 (IL-12) immunotherapy, at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25th – 30th, in Chicago, IL.

PASADENA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- GenVivo, Inc. (GVO) a private, clinical stage biopharmaceutical company with breakthrough “off-the-shelf” gene vector immunotherapies to treat cancer, announces the presentation of GEN2 Phase 1 clinical trial results in adult patients with hepatocellular carcinoma or tumors metastatic to the liver (NCT04313868), at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-10, in Houston, TX.

PASADENA, Calif., June 27, 2024 (GLOBE NEWSWIRE) --  GenVivo, Inc., a private, clinical-stage biopharmaceutical company with breakthrough off-the-shelf platforms for cancer gene medicine immunotherapies, announced that it has dosed the first US patient in a Phase I/Ib, open-label, dose-escalation and expansion clinical trial of GEN2. GEN2, GenVivo’s first product candidate to enter clinical development, is a non-replicating mRNA gene therapy vector being developed as a cancer immunotherapy to both kill tumors and activate a patient’s immune system against their individual cancer antigens (neoantigens). GEN2 is an off-the-shelf medicine, providing the advantages of a personalizing therapy without the time delays and expense associated with autologous products or tumor genome sequencing.